Flucloxacillin plasma and urinary concentrations with and without probenecid and urinary biomarker profiles in healthy volunteers
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70663 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Amy Legg und 9 weiteren Autor:innen. Beteiligte Einrichtung: Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia. Hauptthemen laut MEDLINE: Probenecid, Floxacillin, Anti-Bacterial Agents. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Centre of Research Excellence RESPOND.
Abstract (Originalsprache)
Aim
Oral flucloxacillin is widely used for methicillin‐susceptible Staphylococcus aureus (MSSA) infections, but its recommended 6‐hourly dosing may limit adherence. Probenecid inhibits renal tubular secretion of β‐lactams and enhances flucloxacillin exposure, allowing less frequent dosing. This study aimed to determine the effect of repeated dosing of probenecid on serum and urinary concentrations of flucloxacillin and its impact on pharmacodynamic target attainment.
Methods
Ten healthy adults participated. Flucloxacillin was administered intravenously and orally. Oral flucloxacillin was administered with and without probenecid. Rich plasma sampling was undertaken, with analysis by UHPLC–MS/MS. A population PK model was developed and evaluated, followed by Monte Carlo simulations to assess the probability of target attainment (PTA; target of at least 50% fT > MIC at MIC 0.5 mg/L). Urinary biomarkers (NGAL, KIM‐1, glycosaminoglycans), urinary flucloxacillin concentrations and serum creatinine concentrations were monitored.
Results
Across 307 plasma samples, unbound steady state flucloxacillin concentrations were higher with probenecid (median 0.74 mg/L) than without (median 0.30 mg/L; p = .002). Probenecid reduced flucloxacillin clearance from 143 to 46.9 L/h. Simulations showed markedly improved PTA for flucloxacillin 1 g 8 hourly with probenecid (84%) compared with 1 g 6 hourly alone (6%). Urinary flucloxacillin concentrations were reduced with probenecid, consistent with decreased renal clearance. Serum creatinine concentrations and urinary biomarkers remained stable, and only non‐serious adverse events were reported.
Conclusion
Co‐administration of probenecid significantly enhanced flucloxacillin exposure, without serious adverse effects. These findings warrant evaluation in a clinical trial of patients with MSSA infection. Trial Registration Clinical trial registered with ANZCTR: ACTRN12623001155684.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
- Department of Pharmacy, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
- University of Queensland Centre for Clinical Research, Faculty of Health Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Queensland, Australia.
- Antimicrobials Group, Murdoch Children's Research Institute, The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia.
- Infectious Diseases Department, The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia.
- Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.
ORCID-Profile: Amy Legg, Amanda Gwee
Förderung
- Centre of Research Excellence RESPOND
Zitieren
APA
Legg, A., Boast, A., Piera, K., Liu, X., Wallis, S. C., McCarthy, J., Davis, J. S., Tong, S. Y. C., Gwee, A., & Roberts, J. A. (2026). Flucloxacillin plasma and urinary concentrations with and without probenecid and urinary biomarker profiles in healthy volunteers. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70663
Vancouver
Legg A, Boast A, Piera K, Liu X, Wallis SC, McCarthy J, et al. Flucloxacillin plasma and urinary concentrations with and without probenecid and urinary biomarker profiles in healthy volunteers. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70663
BibTeX
@article{Legg2026,
author = {Legg, Amy and Boast, Alison and Piera, Kim and Liu, Xin and Wallis, Steven C and McCarthy, James and Davis, Joshua S and Tong, Steven Y C and Gwee, Amanda and Roberts, Jason A},
title = {Flucloxacillin plasma and urinary concentrations with and without probenecid and urinary biomarker profiles in healthy volunteers},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70663}
}
EUVIMED